EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Screening of candidate analgesics using a patient‐derived human iPSC model of nociception identifies putative compounds for therapeutic treatment

Jack R Thornton, Alberto Capurro, Sally Harwood, Thomas C Henderson, Adrienne Unsworth, Franziska Görtler, Sushma Nagaraja-Grellscheid, Vsevolod Telezhkin, Majlinda Lako, Evelyne Sernagor, Lyle Armstrong iD

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Jack R Thornton und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences Institute, Newcastle University, Newcastle-upon-Tyne, UK. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Analgesics, Nociception, Erythromelalgia. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose In this study, we applied an induced pluripotent stem cell (iPSC)‐based model of inherited erythromelalgia (IEM) to screen a library of 281 small molecules, aiming to identify candidate pain‐modulating compounds. Experimental approach Human iPSC‐derived sensory neuron‐like cells, which exhibit action potentials in response to noxious stimulation, were evaluated using whole‐cell patch‐clamp and microelectrode array (MEA) techniques. Key results Sensory neuron‐like cells derived from individuals with IEM showed spontaneous electrical activity characteristic of genetic pain disorders. The drug screen identified four compounds (AZ106, AZ129, AZ037 and AZ237) that significantly decreased spontaneous firing with minimal toxicity. The calculated IC 50 values indicate the potential efficacy of these compounds. Electrophysiological analysis confirmed the compounds’ ability to reduce action potential generation in IEM patient‐specific iPSC‐derived sensory neuron‐like cells. Conclusions and implications Our screening approach demonstrates the reproducibility and effectiveness of human neuronal disease modelling offering a promising avenue for discovering new analgesics. These findings address a critical gap in current therapeutic strategies for both general and neuropathic pain, warranting further investigation. This study highlights the innovative use of patient‐derived iPSC sensory neuronal models in pain research and emphasises the potential for personalised medicine in developing targeted analgesics. Key points Utilisation of human iPSCs for efficient differentiation into sensory neuron‐like cells offers a novel strategy for studying pain mechanisms. IEM sensory neuron‐like cells exhibit key biomarkers and generate action potentials in response to noxious stimulation. IEM sensory neuron‐like cells display spontaneous electrical activity, providing a relevant nociceptive model. Screening of 281 compounds identified four candidates that significantly reduced spontaneous firing with low cytotoxicity. Electrophysiological profiling of selected compounds revealed promising insights into their mechanisms of action, specifically modulating the Na V 1.7 channel for targeted analgesia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induced Pluripotent Stem CellsAnalgesicsNociceptionErythromelalgiaHumansDrug Evaluation, PreclinicalAction PotentialsSensory Receptor Cells

Stichwörter der Autor:innen

analgesic candidatesdrug screeningelectrophysiologyinduced pluripotent stem cells (iPSCs)inherited erythromelalgia (IEM)sensory neuron

Substanzen

Analgesics

Autor:innen und Institutionen

  • Biosciences Institute, Newcastle University, Newcastle-upon-Tyne, UK.
  • Bioinformatics Support Unit, Newcastle University, Newcastle-upon-Tyne, UK.
  • Department of Biological Sciences, University of Bergen, Bergen, Norway.
  • School of Dental Sciences, Newcastle University, Newcastle-upon-Tyne, UK.

ORCID-Profile: Lyle Armstrong

Förderung

  • Medical Research Council

Zitieren

APA

Thornton, J. R., Capurro, A., Harwood, S., Henderson, T. C., Unsworth, A., Görtler, F., Nagaraja-Grellscheid, S., Telezhkin, V., Lako, M., Sernagor, E., & Armstrong, L. (2025). Screening of candidate analgesics using a patient‐derived human iPSC model of nociception identifies putative compounds for therapeutic treatment. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70339

Vancouver

Thornton JR, Capurro A, Harwood S, Henderson TC, Unsworth A, Görtler F, et al. Screening of candidate analgesics using a patient‐derived human iPSC model of nociception identifies putative compounds for therapeutic treatment. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70339

BibTeX
@article{Thornton2025,
  author = {Thornton, Jack R and Capurro, Alberto and Harwood, Sally and Henderson, Thomas C and Unsworth, Adrienne and Görtler, Franziska and Nagaraja-Grellscheid, Sushma and Telezhkin, Vsevolod and Lako, Majlinda and Sernagor, Evelyne and Armstrong, Lyle},
  title = {Screening of candidate analgesics using a patient‐derived human iPSC model of nociception identifies putative compounds for therapeutic treatment},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70339}
}
Kostenlos starten →